Astellas to Present Data from Expanding Oncology Portfolio During the 2021 ASCO Annual Meeting

Published by W Butcher on

Astellas’ ambitious innovation and committed collaboration support new research on investigational and approved therapies in hard-to-treat cancers TOKYO, May 17, 2021 /PRNewswire/ — Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) will share new data across its oncology portfolio during the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting from June 4-8, 2021. Covering three approved treatments and one investigational therapy, the 12 Astellas-sponsored abstracts underscore the company’s commitment to advancing treatment options for difficult-to-treat cancers, including bladder, prostate and gastric/gastroesophageal junction (GEJ) cancers, as well as acute myeloid leukemia (AML).

Read More…

Categories: Uncategorized

0 Comments

Leave a Reply

Avatar placeholder

Your email address will not be published.